Cross-stakeholder action is key to ensuring continued patient access to improved treatments in oncology (Guest blog)
A blog by Aikaterini Fameli, PhD Global Oncology Policy Lead, GSK and Vice-Chair of the EFPIA Oncology Platform on behalf of the EFPIA Oncology Platform Endpoints working group.
The launch of Europe's Beating Cancer Plan has renewed the European Union’s commitment to cancer prevention, diagnosis, treatment and care, and prioritised access to innovation as a key action. Scientific advances in cancer treatments are improving survival rates and quality of life for cancer patients. However, while regulatory agencies have continued to evolve the criteria for bringing new oncology medicines to patients, the criteria used for reimbursing new therapies in oncology has not been adapted to keep pace with innovation.